Fairmount Funds Management LLC - 10 Jul 2025 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Role
Director
Signature
/s/ Tomas Kiselak for Fairmount Funds Management LLC
Issuer symbol
COGT
Transactions as of
10 Jul 2025
Net transactions value
+$24,999,993
Form type
4
Filing time
14 Jul 2025, 16:30:37 UTC
Previous filing
23 Jun 2025
Next filing
19 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fairmount Funds Management LLC Director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak for Fairmount Funds Management LLC 14 Jul 2025 0001802528

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COGT Common Stock Purchase $24,999,993 +2,777,777 +45% $9.00 9,003,418 10 Jul 2025 Fairmount Healthcare Fund II LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Remarks:

This Form 4 is filed jointly with Fairmount Healthcare Fund II GP LLC. The Reporting Person may be deemed a director by deputization of Issuer by virtue of the fact that Peter Harwin serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.